Navigation Links
Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program

SUNNYVALE, Calif., July 9 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced the appointment of leading molecular epidemiologist and expert on Healthcare Associated Infections, Fred Tenover, Ph.D., as Senior Director of Scientific Affairs. Dr. Tenover will serve as a liaison with the Infection Control community and will lead Cepheid's Healthcare Associated Infection (HAI) Consortium program.

"The objective of the Cepheid HAI Consortium is to establish global connections between hospital laboratories and leading academic laboratories in order to track evolving drug resistance patterns, virulence determinants, and the emergence of new strains associated with specific HAIs. The resulting information will be used in the design of rapid and definitive new tests for HAIs and for ensuring that Cepheid's leadership position in this area is maintained and expanded," said David H. Persing, M.D., Ph.D., Chief Medical and Technology Officer at Cepheid. "Dr. Tenover is a noted microbiologist and authority on HAI-associated organisms and as such, is uniquely qualified to head Cepheid's HAI Consortium Program. I am extremely pleased to welcome such an accomplished scientist to our team and look forward to Fred's contribution as we continue to expand and refine our menu of molecular tests in this important developing market."

Dr. Tenover currently holds the position of Distinguished Consultant and Director, Office of Antimicrobial Resistance, Centers for Disease Control and Prevention, Atlanta, GA. In addition, Dr. Tenover is Director, Centers for Disease Control and Prevention/World Health Organization Collaborating Center for Global Antimicrobial Resistance Monitoring, Atlanta, GA and is Adjunct Professor in the Department of Epidemiology, Emory University School of Public Health, Atlanta, GA.

"Finding effective treatment for the increasing number of multiple antibiotic resistant HAIs has become a serious challenge for physicians not only in U.S. hospitals but around the world," said Dr. Tenover. "Providing physicians with the critical laboratory data they need to make decisions within a few hours instead of a few days will not only save lives but will help control the spread of infections in healthcare settings. I am delighted to have the opportunity to join forces with the distinguished team of scientists at Cepheid to confront the increasing burden of HAIs on human health."

Dr. Tenover is expected to join the Cepheid team in early October, 2008.

About Cepheid

Cepheid (Nasdaq: CPHD), based in Sunnyvale, Calif., is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The Company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Cepheid's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the Company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market.

This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to future product development. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: unforeseen development and manufacturing problems; our ability to successfully obtain regulatory approvals and introduce new products in the clinical market; the performance and market acceptance of new products; the failure of products to perform as expected, whether due to manufacturing errors, defects or otherwise; the impact of competitive products and pricing; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2007 and in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.


For Media For Cepheid Investor

Inquiries: Inquiries:

Jared Tipton Jacquie Ross

Cepheid Corporate Cepheid Investor

Communications Relations

408-400-8377 408-400-8329

SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. McKool Smith Adds Noted Litigator in New York
2. Life Sciences Industry Reaches Crossroad Say Noted Pillsbury Attorneys
3. Industry Veterans Join Molecular Imprints Management Team
4. New molecular imaging techniques may lead to advances in disease treatment
5. Michigan Tech scientist models molecular switch
6. 3M Discontinues Collaboration with Gen-Probe to Develop Molecular Tests for Healthcare-Associated Infections
7. Molecular changes in brain fluid give insight into brain-damaging disease
8. Xceed Molecular Grants Gen-Probe License to Xceeds Flow-Thru Chip(R) Technology for Multiplex Molecular Diagnostics
9. Gen-Probe Launches Cash Tender Offer to Acquire Belgian Molecular Diagnostics Company Innogenetics
10. Xceed Molecular Features Ziplex(R) Automated Gene-Expression System at the Biomarker World Congress, Booth 16
11. Pathway Diagnostics Announces Commercial Availability of Second Generation SensiTrop(TM) II Molecular HIV Co-receptor Tropism Assay
Post Your Comments:
(Date:10/8/2015)... 2015  Genetic testing for mutations beyond those currently ... more couples at risk of having a child with ... the 2015 American Society of Human Genetics (ASHG) Annual ... Baltimore, Maryland . The study is one of ... ) are presenting at the conference this week demonstrating ...
(Date:10/8/2015)... Oct. 8, 2015 Celemics, a global pioneer ... the North American market with the establishment of Celemics ... and Europe , has secured itself ... Enrichment methodology and sample preparation for DNA sequencing and ... hereditary and somatic genetic testing more accurately, quickly, and ...
(Date:10/8/2015)... 2015 Nobel Prize in Chemistry has been awarded to ... Aziz Sancar , who earned his PhD in molecular and cell ... one of three scientists who received the Nobel Prize for their ... a molecular level.  --> Aziz Sancar , who earned ... Dallas in 1977, is one of three scientists who ...
(Date:10/8/2015)... 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, today announced its ... taking place in the month of October: ... RepliCel will be presenting at the annual Partnering ... Mesa to be held October 7-9 in ...
Breaking Biology Technology:
... was at a security conference and stayed at a hotel, ... claimed that they had implemented it so only those on ... ,I do not purchase wireless Internet service when Im at ... the seminar hosts office. Out of curiosity, on my second ...
... Commerce has announced that it is producing the Wisconsin ... Thursday, September 25, from 8:30 a.m. to 3:45 p.m. ... , ,Wisconsins medical device and technology cluster is ... state, said Department of Commerce (Commerce) Secretary Cory L. ...
... all things e-commerce will speak to cutting-edge Madisonians Thursday evening ... Club Majestic, 115 King Street in downtown Madison. , ,Nationally ... about how e-commerce is coming out of the weeds after ... Some companies are finally learning how to please consumers and ...
Cached Biology Technology:
(Date:9/10/2015)... LONDON , Sept. 10, 2015 Report ... thus far not quite delivered upon previous expectations of ... might be the breakthrough year in which wearables begin ... been expected. One of the main reasons is the ... disrupt not only the SmartWatches market, but the overall ...
(Date:9/8/2015)... , Sept. 8, 2015   TREW Marketing ... new survey, Smart Marketing for Engineers TM : ... engineering professionals reveals insightful findings about engineers, preferences for ... of content engineers most value and trust, and where ... Marketers targeting technical audiences grapple with how to best ...
(Date:9/2/2015)... Biometric technology ... system which uses identical human characteristic such as ... and finger print. Increasing number of terror attacks ... which provides high level of security. Traditional security ... are vulnerable to attacks. Furthermore, Biometric technology uses ...
Breaking Biology News(10 mins):
... adults living closer to a fast food restaurant had a ... away from fast food, according to researchers at The University ... particularly strong among those with a lower income. ... of Public Health indicates higher BMI associates with residential ...
... relationship between the heritable risk for schizophrenia and low ... associated with cognitive impairments that may cause functional disability. ... to the risk for developing schizophrenia. For example, reduced ... Also, these deficits may be present in healthy relatives ...
... hematopoiesis at sites outside the bone marrow in ... (LMU) in Munich now show that a specific type ... blood cells. Balanced hematopoiesis is essential for the ... takes place mainly in the liver and the spleen. ...
Cached Biology News:
... Blunt TOPO PCR Cloning ... designed for cloning and ... PCR products. The pCR4Blunt-TOPO ... Cloning and greater than ...
... 5 ml CELLection Dynabeads (4.5 m) coated ... epithelial antigen EpCAM and DNase Releasing Buffer. ... of epithelial tumour cells directly from blood, ... can be enriched from bone marrow. Enriched ...
Recombinant Human CCL21/6Ckine (Mucin Stalk Chimera)...
Recombinant Human Erythropoietin (Tissue Culture Grade)...
Biology Products: